The 2022 annual report, outlining the current development pipeline of new drug-based treatments for Parkinson’s, has been published.
Cure Parkinson’s is funding Professor Oliver Bandmann at the University of Sheffield to establish a nationwide infrastructure for a study group focused specifically on conducting clinical trials for Parkinson’s.
On Tuesday 10 May, the City’s leading wealth management professionals gathered in the historic Merchant Taylors’ Hall for the 34th annual Gulls’ Eggs Luncheon, raising over £72k for Parkinson’s research.
The findings of the phase 1a clinical trial of Anle138b have been published. Anle138b is a new drug that targets the build-up of alpha synuclein, a protein that clumps together in Parkinson’s.
Theme: Why diabetes drugs might be an important potential line of treatment for Parkinson’s. The meeting was recorded and is available to re-watch now